OCS
Oculis Holding AG
NASDAQ · Healthcare · Biotechnology · CH
$7.28
−4.59%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 886.69x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 1.68x
- Price / sales
- 1520.57x
- Price / cash flow
- -5.61x
Enterprise value
- Enterprise value
- $453.9M
- EV / sales
- 1531.01x
- EV / EBITDA
- -4.75x
- EV / EBIT
- -4.27x
- Market cap
- $450.8M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026